Bispecific T-cell engagers represent a significant advancement in cancer treatment. These therapies work by directly linking immune cells to cancer cells and have been approved for various hematologic and solid tumors. Numerous ongoing studies are exploring their use in earlier lines of therapy or in combination with other treatments, making the establishment of bispecific antibody therapy programs in both inpatient and outpatient settings essential to serve patients best.
Developing these programs requires substantial effort, including creating protocols for adverse effect management, educating staff and patients, and careful financial planning to address logistical challenges. This undertaking demands inter-professional collaboration among various healthcare providers and efficient systems to ensure clear and timely communication.
To assist programs planning to initiate a bispecific antibody therapy program, NCODA has developed a playbook as an essential guidance on epcoritamab-bysp (EPKINLY®), an off-the-shelf bispecific CD20/CD3 T-cell engager approved for treating diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), and follicular lymphoma (FL). By providing this information, we aim to facilitate the successful integration and accessibility of this drug into oncology practices, both in inpatient and outpatient settings.
Learn more and read the full EPCORITAMAB-BYSP (EPKINLY®) PLAYBOOK HERE.
References
- Zhou S, Liu M, Ren F, Meng X, Yu J. The landscape of bispecific T cell engager in cancer treatment. Biomark Res. 2021;9(1):38. doi:10.1186/s40364-021-00294-9.
- Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276. doi:10.3389/fimmu.2022.1035276.
- Mahmoudjafari Z, Ali A, Davis J, Sandahl T, Nachar V, Mancini R. Seamless navigation of bispecific therapies: Optimizing management and outpatient access with a focus on coordination. J Adv Pract Oncol. Published online September 11, 2024. doi:10.6004/ JADPRO.2024.15.8.15.
- Epkinly (epcoritamab-bysp) [Package Insert]. Plainsboro, NJ. Genmab US, Inc. And North Chicago, IL: AbbVie Inc. 2024.
